Profusa, Inc.PFSA
Health Care · Health Care Equipment & Services · NASDAQ · United States
Based in Berkeley, California, Profusa is a digital health company developing tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. Its long-lasting, injectable biosensors and intelligent data platform aim to provide people with a personalized biochemical signature that clinicians can trust. The company completed a 1-for-4 reverse stock split effective August 14, 2026.
Key ratios
FCF / Sales
-2065.6%2024
2023
-9790.6%
ROA
-505.7%2025
2024
-113.3%2023
-259.5%
Revenue growth
-100.0%TTM
2024
122.2%
Recent news
Profusa Receives ISO 13485:2016 Certificate from GMED
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
Profusa, Inc. Receives Nasdaq Compliance Determination
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
Track PFSA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer